Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Target price


15.04.24 / Tradegate WKN: 165417 / Symbol: NKTR / Name: Nektar / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Nektar Therapeutics Stock

Nektar Therapeutics took a tumble today and lost -€0.163 (-10.420%).
Our community is currently high on Nektar Therapeutics with 3 Buy predictions and 1 Sell predictions.
Based on the current price of 1.47 € the target price of 3 € shows a potential of 103.67% for Nektar Therapeutics which would more than double the current price.
For the coming years our community has positive and negative things to say abot the Nektar Therapeutics stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Unique positioning" there were negative voices in the community.

Nektar is a clinical-stage biopharmaceutical company focused on developing treatments for cancer, autoimmune diseases, and chronic pain. The company's pipeline includes product candidates based on its proprietary drug delivery technology, which improves the delivery and effectiveness of drugs in the body. Some of its most advanced candidates include NKTR-214, a cancer immunotherapy, and NKTR-181, a non-opioid pain medication. Nektar is listed on the NASDAQ exchange under the ticker symbol NKTR.

Pros and Cons of Nektar Therapeutics in the next few years

W********* I********* f** t** n*** y****
S********** s********
C******** o* t** e**********
M***** P*******
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Nektar Therapeutics vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Nektar Therapeutics -10.420% 21.535% 89.966% 75.190% 195.724% -90.893% -
Ironwood Pharmaceuticals -0.670% -0.676% -6.962% -25.758% -29.327% -17.416% -36.856%
Novocure Ltd -6.070% -8.308% -6.809% -79.006% -16.112% -92.786% -
Iovance Biotherapeutics Inc. -3.750% -7.063% -12.343% 117.861% 43.251% -55.999% -

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-06-23

In general, Nektar Therapeutics (NKTR) from the Biotechnology & Medical Research industry presents an interesting financial profile. The company seems to have struggled with net income over the last few years but maintains a consistent cash position and sizeable investments. Below is a comprehensive analysis of the company's financials, including notable pros and cons to consider.

Solid Cash Position: NKTR has maintained a reasonably strong cash position throughout the years, with an end-period cash balance of $102.6 million in 2020, $25.2 million in 2021, and $88.2 million in 2022. As of Q1 2023, the cash balance stands at $76.9 million, indicating that the company has been able to consistently generate and preserve cash.

Growing Total Assets: The company registered an increase in total assets from $1.54 billion in 2020 to $1.12 billion in 2021, although there was then a decrease to $710.6 million in 2022. Despite the recent decline, the overall trend in asset growth signifies that the business is expanding.


Nektar Therapeutics (NASDAQ: NKTR) had its "underweight" rating re-affirmed by analysts at JPMorgan Chase & Co..
Ratings data for NKTR provided by MarketBeat
Show more

Nektar Therapeutics (NASDAQ: NKTR) was upgraded by analysts at TD Cowen from a "market perform" rating to an "outperform" rating.
Ratings data for NKTR provided by MarketBeat
Show more

Prediction Sell
Perf. (%) -50.72%
Target price 1.881
Ends at 28.02.24

Nektar Therapeutics (NASDAQ: NKTR) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $3.00 to $2.00. They now have a "sell" rating on the stock.
Ratings data for NKTR provided by MarketBeat
Show more